Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | MERTK | Q12866 | 2/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 7/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.30 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL343925 | 0.86 | CRHR1 (0.33) | ADORA3ADORA1MERTKCRHR1NR3C1 | |
| SCHEMBL342898 | 0.86 | CRHR1 (0.33) | ADORA3ADORA1MERTKCRHR1NR3C1 | |
| SCHEMBL342899 | 0.86 | CRHR1 (0.33) | ADORA3ADORA1MERTKCRHR1NR3C1 | |
| SCHEMBL28651973 | 0.83 | GRM2 (0.34) | ADORA3ADORA1MERTKCRHR1NR3C1 | |
| SCHEMBL343114 | 0.82 | CRHR1 (0.33) | ADORA3ADORA1CRHR1NR3C1MAPK1 | |
| SCHEMBL342887 | 0.80 | MITF (0.38) | ADORA3ADORA1CRHR1NR3C1LMNA | |
| SCHEMBL342889 | 0.80 | MITF (0.38) | ADORA3ADORA1CRHR1NR3C1LMNA | |
| SCHEMBL27156539 | 0.80 | MERTK (0.40) | ADORA3ADORA1MERTKCRHR1GRM2 | |
| SCHEMBL10167368 | 0.80 | LMNA (0.36) | MERTKAXLTYRO3LMNAKAT2B | |
| SCHEMBL27156541 | 0.80 | MERTK (0.40) | ADORA3ADORA1MERTKCRHR1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637529-B2 | Pyrazolo[3,4-d]pyrimidine compounds | AbbYie Inc. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120015963-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2011156698-A2 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015963-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | CHUK, MAP2K2, CDK3 | ADORA3 420/4885ADORA1 477/4885MERTK 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.